Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrosine for Psychosis in Velo-Cardio-Facial Syndrome
NCT01127503Phase 2Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psychosis comparing Metyrosine with Placebo (2 arms). Primary endpoint: Safety of Metyrosine at 13 weeks. Started Jun 2010; status: terminated.
02
Drugs
metyrosine
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT01127503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127503.